A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | Product name | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T9920 | Evolocumab | 1256937-27-5 | 98% |
Evolocumab
|
Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9). | ||||
T78269 | RMP1-14 | 98% |
RMP1-14
|
|
RMP1-14 is an IgG1-like immunoglobulin and anti-Mouse PD-1 antibody that blocks PD-1/PD-L1 signaling. | ||||
T36653 | Anti-SARS-80R mAb | 98% |
Anti-SARS-80R mAb
|
|
Anti-SARS-80R mAb (SARS-80R) is a human IgG1 monoclonal antibody that is derived from CHO cells. Its main function is to selectively bind to the Spike (S1) prote... | ||||
T36654 | Anti-SARS-CoV-2 Spike mAb (CR3022) | 98% |
Anti-SARS-CoV-2 Spike mAb (CR3022)
|
|
Anti-SARS-CoV-2 Spike mAb (CR3022) is a human monoclonal IgG1 antibody derived from CHO cells. It specifically targets the S1 domain of the Spike protein in both... | ||||
T9923 | Nimotuzumab | 828933-51-3 | 98% |
|
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR). | ||||
T36651 | Anti-MERS-2E6 mAb | 98% |
Anti-MERS-2E6 mAb
|
|
Anti-MERS-2E6 mAb (MERS-2E6), a human IgG1 neutralizing antibody, is expressed in CHO cells. It effectively competes with the virus Spike protein for binding to ... | ||||
T36655 | Anti-Spike-RBD mAb | 98% |
Anti-Spike-RBD mAb
|
|
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of spike protein and ACE2 is a potential therapeutic approach f... | ||||
T9922 | Matuzumab | 339186-68-4 | 98% |
Matuzumab
|
Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in ... | ||||
T35389 | Sarilumab (anti-IL-6Rα) | 98% |
Sarilumab (anti-IL-6Rα)
|
|
Sarilumab (anti-IL-6Rα) is a useful organic compound for research related to life sciences and the catalog number is T35389. | ||||
T36656 | Anti-Spike-RBD Single Domain mAb | 98% |
Anti-Spike-RBD Single Domain mAb
|
|
The Anti-Spike-RBD Single Domain mAb is a monoclonal antibody derived from CHO cells in Alpaca. It is composed of VHH-huFc and exhibits a strong affinity for the... | ||||
T12706 | Reslizumab | 241473-69-8 | 98% |
|
Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. | ||||
T9931 | Meplazumab | 2413715-21-4 | 98% |
meplazumab
|
meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia. | ||||
T36652 | Anti-MERS-3A1 mAb | 98% |
Anti-MERS-3A1 mAb
|
|
Anti-MERS-3A1 mAb (MERS-3A1) is a high-affinity human monoclonal IgG1 antibody derived from CHO cells. It effectively inhibits the interaction between the MERS-C... | ||||
T35396 | Spartalizumab (anti-PD-1) | 98% |
Spartalizumab (anti-PD-1)
|
|
Spartalizumab (anti-PD-1) is a useful organic compound for research related to life sciences and the catalog number is T35396. | ||||
T9921 | Infliximab | 170277-31-3 | 99.70% |
|
Infliximab is a humanized antibody against tumor necrosis factor α TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis. | ||||
T9906 | Ipilimumab | 477202-00-9 | 99.60% |
|
Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibito... | ||||
T9911 | Tocilizumab | 375823-41-9 | 99.50% |
|
Tocilizumab anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor | ||||
T9930 | Secukinumab | 875356-43-7 | 99.10% |
Secukinumab
|
Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatme... | ||||
T9905 | Cetuximab | 205923-56-4 | 98.60% |
|
Cetuximab (anti-EGFR) a novel molecular-targeted agentis an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EG... | ||||
T37535 | Camrelizumab | 1798286-48-2 | 98.6% |
|
Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up ... |